A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of
using molecularly guided therapy in combination with standard therapy followed by a
Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO
maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
Giselle SaulnierSholler Giselle Sholler
Collaborators:
Beat NB Cancer Foundation Because of Ezra Dell, Inc. K C Pharmaceuticals Inc. Team Parker for Life